Catalog No.S1198
1 Reviews

Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Irinotecan Chemical Structure

Irinotecan Chemical Structure
Molecular Weight: 586.68

Validation & Quality Control

Customer Reviews(1)

Quality Control & MSDS

Related Compound Libraries

Product Information

  • Compare Topoisomerase Inhibitors
    Compare Topoisomerase Products
  • Research Area

Product Description

Biological Activity

Description Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.
Targets Topo I (HT-29 cells) Topo I (LoVo cells)
IC50 5.17 μM [1] 15.8 μM [1]
In vitro Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. [1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. [2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. [3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. [4]
In vivo In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. [5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. [6]
Features Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines LoVo and HT-29 cells
Concentrations 0 μM -100 μM
Incubation Time 48 hours
Method Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.

Animal Study: [5]

Animal Models Female nude mice with COLO 320 and WiDr xenografts
Formulation 0.9% NaCl
Dosages 20 mg/kg
Administration Administered via i.p.
Solubility 30% propylene glycol, 5% Tween 80, 65% D5W, , 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


[1] Pavillard V, et al. Cancer Chemother Pharmacol. 2002, 49(4), 329-335.

[2] Tobin P, et al. Br J Clin Pharmacol. 2006, 62(1), 122-129.

view more

Clinical Trial Information( data from

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02095132 Not yet recruiting Recurrent Childhood Medulloblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Neuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) 2014-03 Phase 1|Phase 2
NCT01921751 Not yet recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer Radiation Therapy Oncology Group|National Cancer Institute (NCI) 2014-03 Phase 2
NCT02110953 Not yet recruiting Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer Fox Chase Cancer Center|National Cancer Institute (NCI) 2014-04 Phase 1
NCT02049593 Not yet recruiting Metastatic Cancer|Unspecified Adult Solid Tumor Jonsson Comprehensive Cancer Center|Translational Research in Oncology-US (TRIO-US) 2014-04 Phase 1
NCT02055196 Not yet recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor City of Hope Medical Center|National Cancer Institute (NCI) 2014-06 Phase 1

Chemical Information

Download Irinotecan SDF
Molecular Weight (MW) 586.68


CAS No. 97682-44-5
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Synonyms CPT-11, SN-38
Solubility (25°C) * In vitro DMSO 7 mg/mL (11 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Research Area

Customer Reviews (1)

Click to enlarge
Source Irinotecan purchased from Selleck
Method Cell viability assay
Cell Lines pancreatic cancer cells
Concentrations 0-100 μM
Incubation Time 72 h
Results Irinotecan potently inhibited the survival of Panc1 cells in a dose-dependent manner.

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Topoisomerase Products

  • Beta-Lapachone

    Beta-Lapachone is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. Phase 2.

  • Voreloxin (SNS-595)

    Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.

  • Doxorubicin (Adriamycin)

    Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

  • Etoposide

    Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

  • Camptothecin

    Camptothecin is a specific inhibitor of DNA topoisomerase I (Topo I) with IC50 of 0.68 μM. Phase 2.

  • Idarubicin HCl

    Idarubicin HCl is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL.

    Features:Idarubicin is a substrate for CYP450 2D6 and 2C9.

  • SN-38

    SN-38 is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks.

  • Topotecan HCl

    Topotecan (NSC 609699) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM, respectively.

    Features:Topotecan is a water-soluble derivative of camptothecin.

  • Mitoxantrone

    Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively

Recently Viewed Items

Tags: buy Irinotecan | Irinotecan ic50 | Irinotecan price | Irinotecan cost | Irinotecan solubility dmso | Irinotecan purchase | Irinotecan manufacturer | Irinotecan research buy | Irinotecan order | Irinotecan mouse | Irinotecan chemical structure | Irinotecan mw | Irinotecan molecular weight | Irinotecan datasheet | Irinotecan supplier | Irinotecan in vitro | Irinotecan cell line | Irinotecan concentration | Irinotecan nmr
Contact Us